Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study to Assess Drug Interactions and Food Effect of Navlimetostat in Healthy Female Participants
NCT07800897Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of navlimetostat in cancer (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Area under the concentration-time curve from time zero to 192 hours and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07800897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800897.